Table 3.
Median PFS and OS Time by ERCC1 Polymorphisms
| ERCC1 Genotype | No. of Patients | Median PFS (months) | P | Median OS (months) | P |
|---|---|---|---|---|---|
| All participants | |||||
| Codon 118 in ERCC1 | .410 | .323 | |||
| C/C | 40 | 19.6 | 42.7 | ||
| C/T | 101 | 18.1 | 60.9 | ||
| T/T | 92 | 22.8 | 52.7 | ||
| C8092A in ERCC1 | .051 | .047 | |||
| C/C | 131 | 24.1 | 68.6 | ||
| C/A or A/A | 102 | 17.7 | 51.6 | ||
|
| |||||
| IP arm subset | |||||
| Codon 118 in ERCC1 | .751 | .385 | |||
| C/C | 17 | 23.8 | 42.7 | ||
| C/T | 51 | 18.4 | 66.9 | ||
| T/T | 38 | 24.1 | 68.6 | ||
| C8092A in ERCC1 | .038 | .046 | |||
| C/C | 61 | 27.9 | 81.4 | ||
| C/A or A/A | 45 | 18.3 | 52.6 | ||
|
| |||||
| IV arm subset | |||||
| Codon 118 in ERCC1 | .440 | .725 | |||
| C/C | 23 | 17.8 | 47.1 | ||
| C/T | 50 | 16.9 | 59.9 | ||
| T/T | 54 | 20.9 | 50.4 | ||
| C8092A in ERCC1 | .465 | .333 | |||
| C/C | 70 | 20.3 | 56.5 | ||
| C/A or A/A | 57 | 17.7 | 49.7 | ||
NOTE. PFS and OS were estimated by Kaplan-Meier method, and median times are provided in months from enrollment. Log-rank test was used to compare survival distributions between groups.
Abbreviations: PFS, progression-free survival; OS, overall survival; IP, intraperitoneal cisplatin and paclitaxel; IV, intravenous cisplatin and paclitaxel.